Navigation Links
MedImmune Publishes New Data in Nature Immunology Demonstrating The,Role HMGB1 May Play in Systemic Autoimmune Diseases

- Preclinical Data Support Rationale for Targeting Pro-Inflammatory Protein -

GAITHERSBURG, Md., April 18, 2007 /PRNewswire-FirstCall/ -- MedImmune, Inc. today announced the publication of preclinical study data demonstrating a role for high mobility group box protein-1 (HMGB1), a nuclear DNA-binding protein, in the pathology of systemic autoimmune diseases such as systemic lupus erythematosus (SLE or lupus) and rheumatoid arthritis. Data to be published in the May 2007 issue of Nature Immunology show that HMGB1 is an essential component of DNA-immune complexes that stimulate immune cells to produce potent inflammatory proteins. The data supplement earlier preclinical evidence that HMGB1 may be an important factor in the sequence of events that result in severe tissue damage following injury or during chronic inflammation. The data also suggest that a blocking antibody to HMGB1 may provide protection in chronic inflammatory diseases.

"MedImmune is committed to developing innovative treatments for inflammatory diseases, and among our key areas of focus are the disease pathology of lupus and the role of B cells in autoimmunity," said Anthony J. Coyle, vice president, research and development, and head, inflammation and autoimmunity research. "These data, applicable to several programs within our pipeline, demonstrate a novel mechanism by which HMGB1 mediates B cell activation and may contribute to the pathogenesis of autoimmune disorders."

HMGB1's potential role in chronic inflammatory diseases is the focus of ongoing preclinical research conducted by MedImmune in collaboration with its partner, Critical Therapeutics, Inc. The Nature Immunology article, titled "Toll-like receptor 9-dependent activation by DNA containing immune complexes is mediated by HMGB1 and RAGE," contains data showing that HMGB1 is a key component of DNA-immune complexes that stimulate activation of B cells and plasmacytoid den dritic cells (pDCs) via the toll-like receptor 9 pathway (TLR9). Both B cells and pDCs are associated with immune system disorders such as lupus. The data also suggest that HMGB1 DNA-immune complexes augment production of inflammatory proteins by interacting with the receptor for advanced glycation end products (RAGE).

About HMGB1

HMGB1, a pro-inflammatory protein secreted by different cell types, is part of the body's response to trauma and infection. HMGB1 is expressed at high levels beginning 12 to 72 hours after an injury, which is about the time inflammation-associated tissue damage begins. Because of the timing and duration of expression of HMGB1, it may be an important factor in the sequence of events that result in severe tissue damage following injury or during chronic inflammation.

About Lupus

According to the Lupus Foundation of America, approximately 1.5 million Americans may suffer from some form of lupus, a chronic inflammatory disease that causes the body to attack its own tissues and organs, including the skin, joints, blood and kidneys. Treatments for lupus include anti-inflammatory drugs, antimalarials, corticosteroids and drugs approved for other purposes, such as immunosuppressive agents given to cancer patients undergoing chemotherapy or medicines developed to treat patients with arthritis. Lupus occurs about 10 times more frequently in adult females than adult males, and is two to three times more common among African Americans, Hispanics, Asians and Native Americans.

About MedImmune, Inc.

MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With more than 2,500 employees worldwide, MedImmune is headquartered in Maryland. For more information, visit the company's website at

This announcement may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties, in particular, related to the research and development of antibodies targeting HMGB1. Such statements reflect management's current views and are based on certain assumptions about the success of this program. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties discussed in MedImmune's filings with the SEC. MedImmune is developing HMGB1-related product candidates for potential future marketing. There can be no assurance that such development efforts will succeed, that such products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success.

CONTACT: Media, Kate Barrett, +1-301-398-4320, or Investors, BeatricePierre, +1-301-398-4905, both of MedImmune, Inc.

Web site:

Ticker Symbol: (NASDAQ-NMS:MEDI)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. Infinity and MedImmune Present Updated Phase I Results of IPI-504 in GIST at ASCO Annual Meeting
2. Infinity and MedImmune Announce Updated Data On Ipi-504 to be Presented At ASCO
3. MedImmune Highlights Advances in Inflammatory Disease Pipeline With Series of Data Presentations
4. MedImmune Announces Positive Clinical Results at PAS Annual Meeting From Large Prospective Trial in Prevention of Serious RSV Disease
5. Pediatric Academic Societies Annual Meeting to Feature Data Presentations Related to MedImmune Clinical Programs in Influenza, RSV and hMPV
6. Micromet Achieves Milestone in BiTE Research Collaboration with MedImmune
7. MedImmune and Micromet Publish Data on Novel Anti-Cancer BiTE Molecule
8. Micromet and MedImmune Present Data From Preclinical Study of New BiTE Molecule Targeting CEA
9. Infinity and MedImmune to Present Preclinical Data From Study of Oral Formulation of IPI-504 At AACR
10. Trophos Publishes ALS Article in Journal of Pharmacology and Experimental Therapeutics
11. Arrowhead Subsidiary, Insert, Publishes Interim Phase I Data from Human Clinical Trials for New Cancer Drug
Post Your Comments:
(Date:10/13/2015)... -- Families across the country have filed product ... pharmaceutical company,s blockbuster anti-nausea drug Zofran and congenital ... their fraudulent misrepresentations to prescribing physicians about the ...   Due to the large number of Zofran birth ... Panel on Multidistrict Litigation (JPML) has ordered that ...
(Date:10/13/2015)... LAS VEGAS , Oct. 13, 2015 ... field of vascular medicine and intervention through education and ... its annual conference,  VIVA 2015 . Sixteen trial results, ... be released for the first time on Monday and ... Vegas. --> --> ...
(Date:10/13/2015)... , Oct. 13, 2015   Generational Equity , ... businesses, is pleased to announce the acquisition of its ... Largo, Florida , by Meridian Biomedical, ... September 11, 2015. Florida ... --> Florida . To learn more, ...
Breaking Medicine Technology:
(Date:10/13/2015)... ... 13, 2015 , ... The Lymphoma Research Foundation (LRF) – ... serving the lymphoma community through a comprehensive series of education programs, outreach initiatives ... Commitment to Cure last night at the Mandarin Oriental in New York City. ...
(Date:10/13/2015)... ... 13, 2015 , ... Wimbledon Health Partners , the ... as well as pioneering the way for high schools, colleges and universities to ... Levitt as Chief Financial Officer. Levitt brings over 20 years of financial experience ...
(Date:10/13/2015)... ... October 13, 2015 , ... The added calories and sugar in ... So what is a parent to do? Registered dietitians from Retrofit , the ... this time of year. , “Halloween is a high-calorie holiday,” said Dara Aronow, ...
(Date:10/13/2015)... ... October 13, 2015 , ... The American Institutes for Research ... health staff caring for students who have experienced sexual assault and other trauma. The ... House during the Violence Against Women Act's 21st anniversary. , AIR ...
(Date:10/13/2015)... ... 2015 , ... CURE Media Group, the nation’s leading digital ... with the International Waldenstrom’s Macroglobulinemia Foundation (IWMF) to expand education and ... physicians. , “Waldenstrom’s Macroglobulinemia is a so-called ‘orphan disease’ that typically does ...
Breaking Medicine News(10 mins):